These results indicate that JAK agonists can reverse the inhibitory effect of OSMR silencing on malignant tumor cell behavior, indicating that OSMR enhances aggressive behavior by activating the JAK/STAT3/CCL-2 pathway. The gene discussed is CCL2; the disease is neoplasm.